The Hollings Cancer Center (HCC) at the Medical University of South Carolina (MUSC) seeks renewal of its National Cancer Institute (NCI) designation via the P30 Cancer Center Support Grant (CCSG) mechanism. As South Carolina's (SC) leading academic medical center, MUSC is charged with building basic, translational, clinical, and population-based research programs that address the state's significant healthcare needs. The mission of the HCC is to reduce the cancer burden in SC through transformative research, patient care, prevention, and public policy. To accomplish this mission, HCC leadership built a robust, multidisciplinary center that includes 107 cancer scientists. Innovative, high-impact research is driven by HCC?s four research programs: Cancer Biology, Cancer Immunology, Developmental Cancer Therapeutics, and Cancer Control. The rapid pace of discovery and movement toward effective translational research is supported by five shared research resources: Lipidomics, Flow Cytometry & Cell Sorting, Cell & Molecular Imaging, Biorepository & Tissue Analysis, and Biostatistics. During the current project period, the HCC successfully leveraged CCSG funding and its NCI-designated cancer center status to harness, expand and improve the center?s research capabilities to decrease the state?s cancer burden. HCC supported recruitment of 26 new cancer scientists. The annual direct peer-reviewed extramural research funding (excluding training and career development awards) increased to $21.6M, with $10.5M from NCI. HCC boasts the state?s largest clinical trials operation that provides centralized support for conducting the most contemporary cancer trials. During the past year, the HCC recruited 1,266 patients to interventional studies and 254 patients to non-interventional studies. HCC made significant progress in overcoming the challenges inherent in recruiting racial and ethnic minorities to participate in research. In 2017, 33% of research participants were racial or ethnic minorities, with more than half residing in rural communities federally designated as medically underserved. This progress has been maintained for over two decades by progressive, HCC-led outreach, community engagement, and cancer education services. With the charge of training the next generation of diverse and exceptional cancer physicians and scientists, the center developed the state?s only comprehensive cancer education pipeline for learners across the entire education continuum, from high school through early professional career development. The HCC is committed to providing access to the latest research, educational, and clinical advances to all of South Carolina, and has never been better equipped to fulfill its mission. Led by a new center director appointed in 2017, the HCC will implement its 2023 strategic plan to advance scientific discovery, make impactful contributions to the understanding of cancer biology in a diverse population, and translate discoveries into transformative approaches to cancer control, diagnosis, treatment, and public policy.

Public Health Relevance

The Hollings Cancer Center at the Medical University of South Carolina coordinates scientific research to promote interdisciplinary collaborations and translation of cancer research from the bench to the bedside to the community. Through the funding of the P30 Cancer Center Support Grant, the center provides research resources in support of its scientists, with the goal of reducing the cancer burden in South Carolina.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA138313-12S2
Application #
10243432
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
2009-04-01
Project End
2024-03-31
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
12
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Medical University of South Carolina
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29407
Daenthanasanmak, Anusara; Wu, Yongxia; Iamsawat, Supinya et al. (2018) PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity. J Clin Invest 128:2787-2801
Rosenzweig, Steven A (2018) Acquired Resistance to Drugs Targeting Tyrosine Kinases. Adv Cancer Res 138:71-98
Min, Kyung-Won; Zealy, Richard W; Davila, Sylvia et al. (2018) Profiling of m6A RNA modifications identified an age-associated regulation of AGO2 mRNA stability. Aging Cell 17:e12753
Alawieh, Ali; Langley, E Farris; Weber, Shannon et al. (2018) Identifying the role of complement in triggering neuroinflammation after traumatic brain injury. J Neurosci :
Metelli, Alessandra; Salem, Mohammad; Wallace, Caroline H et al. (2018) Immunoregulatory functions and the therapeutic implications of GARP-TGF-? in inflammation and cancer. J Hematol Oncol 11:24
Helke, Kristi; Angel, Peggi; Lu, Ping et al. (2018) Ceramide Synthase 6 Deficiency Enhances Inflammation in the DSS model of Colitis. Sci Rep 8:1627
DeHart, David N; Lemasters, John J; Maldonado, Eduardo N (2018) Erastin-Like Anti-Warburg Agents Prevent Mitochondrial Depolarization Induced by Free Tubulin and Decrease Lactate Formation in Cancer Cells. SLAS Discov 23:23-33
Scheffel, Matthew J; Scurti, Gina; Wyatt, Megan M et al. (2018) N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner. Cancer Immunol Immunother 67:691-702
Zunke, Friederike; Moise, Alexandra C; Belur, Nandkishore R et al. (2018) Reversible Conformational Conversion of ?-Synuclein into Toxic Assemblies by Glucosylceramide. Neuron 97:92-107.e10
Schutt, Steven D; Wu, Yongxia; Tang, Chih-Hang Anthony et al. (2018) Inhibition of the IRE-1?/XBP-1 pathway prevents chronic GVHD and preserves the GVL effect in mice. Blood Adv 2:414-427

Showing the most recent 10 out of 536 publications